(59 days)
Not Found
No
The device description and performance studies focus on a standard chemical assay methodology (Diazonium salt) and do not mention any AI/ML components or data processing techniques.
No.
This device is an in vitro diagnostic (IVD) assay used for the quantitative measurement of total bilirubin, which aids in diagnosis and management, rather than providing direct therapy.
Yes
The device quantifies total bilirubin, which is explicitly stated to be "used in the diagnosis and treatment of liver, hematological, and metabolic disorders, including hepatitis and disorders of the biliary tract" and "to aid in the diagnosis and management of neonatal jaundice and hemolytic disease of the newborn." These applications fall under the definition of a diagnostic device.
No
The device is an in vitro diagnostic (IVD) assay, which is a reagent kit used with a specific hardware system (ARCHITECT c System) to perform a chemical reaction and measure a substance in a biological sample. It is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The description explicitly states the assay is "used for the quantitation of total bilirubin in human serum or plasma". This involves testing samples taken from the human body.
- Purpose: The intended use also details that the measurement is "used in the diagnosis and treatment of liver, hematological, and metabolic disorders" and to "aid in the diagnosis and management of neonatal jaundice and hemolytic disease of the newborn." This clearly indicates a medical purpose related to diagnosis and treatment.
- Device Description: The description explains the assay is an "automated clinical chemistry assay" that performs a chemical reaction on the sample to measure bilirubin. This is a typical characteristic of an in vitro diagnostic device.
- Sample Type: The assay uses "human serum or plasma," which are biological samples taken from the body.
All these points align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
The Total Bilirubin2 assay is used for the quantitation of total bilirubin in human serum or plasma, of adults and neonates, on the ARCHITECT c System.
Measurement of total bilirubin, an organic compound formed during the normal destruction of red blood cells, is used in the diagnosis and treatment of liver, hematological, and metabolic disorders, including hepatitis and disorders of the biliary tract. In newborn infants, the Total Bilirubin2 assay is intended to measure the levels of total bilirubin (conjugated and unconjugated) in serum or plasma to aid in the diagnosis and management of neonatal jaundice and hemolytic disease of the newborn.
Product codes (comma separated list FDA assigned to the subject device)
CIG, MQM
Device Description
Total (conjugated and unconjugated) bilirubin couples with a diazo reagent in the presence of a surfactant to form azobilirubin. The diazo reaction is accelerated by the addition of surfactant as a solubilizing agent. The increase in absorbance at 548 nm due to azobilirubin is directly proportional to the total bilirubin concentration. Methodology: Diazonium salt.
The configurations of the Total Bilirubin2 reagent kits are described below:
- List Number 04T0920: Tests per cartridge set 225, Number of cartridge sets per kit 4, Tests per kit 900. Reagent 1 (R1) 44.5 mL, Reagent 2 (R2) 14.5 mL.
- List Number 04T0930: Tests per cartridge set 450, Number of cartridge sets per kit 8, Tests per kit 3600. Reagent 1 (R1) 85.9 mL, Reagent 2 (R2) 26.7 mL.
Active ingredient: Brij L23 (233.333 mL/L) in R1.
Active ingredients: 2,4-dichlorobenzenediazonium 1,5-naphthalenedisulfonate hydrate (1845.000 mg/L) and Brij L23 (100.000 mL/L) in R2.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adults and neonates
Intended User / Care Setting
Prescription Use (Part 21 CFR 801 Subpart D)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Within-Laboratory Precision:
Study Type: Based on guidance from CLSI EP05-A3.
Sample Size: 80 replicates for each sample type.
Key Results:
- Control Level 1 (Mean 1.1 mg/dL): Within-Run SD 0.02, %CV 1.9; Within-Laboratory SD 0.04 (Range 0.02-0.04), %CV 3.4 (Range 1.8-3.4).
- Control Level 2 (Mean 4.2 mg/dL): Within-Run SD 0.04, %CV 0.9; Within-Laboratory SD 0.09 (Range 0.09-0.10), %CV 2.1 (Range 2.0-2.2).
- Panel A (Mean 0.3 mg/dL): Within-Run SD 0.00, %CV 0.0; Within-Laboratory SD 0.00 (Range 0.00-0.03), %CV 0.0 (Range 0.0-9.2).
- Panel B (Mean 13.3 mg/dL): Within-Run SD 0.09, %CV 0.7; Within-Laboratory SD 0.11 (Range 0.09-0.12), %CV 0.8 (Range 0.7-0.9).
- Panel C (Mean 22.3 mg/dL): Within-Run SD 0.15, %CV 0.7; Within-Laboratory SD 0.16 (Range 0.16-0.18), %CV 0.7 (Range 0.7-0.8).
System Reproducibility:
Study Type: Based on guidance from CLSI EP05-A3.
Sample Size: 84 replicates for each sample type.
Key Results:
- Control Level 1 (Mean 1.1 mg/dL): Repeatability SD 0.02, %CV 1.6; Within-Laboratory SD 0.02, %CV 2.1; Reproducibility SD 0.02, %CV 2.2.
- Control Level 2 (Mean 4.5 mg/dL): Repeatability SD 0.03, %CV 0.6; Within-Laboratory SD 0.06, %CV 1.5; Reproducibility SD 0.16, %CV 3.5.
- Panel B (Mean 13.4 mg/dL): Repeatability SD 0.08, %CV 0.6; Within-Laboratory SD 0.10, %CV 0.7; Reproducibility SD 0.57, %CV 4.3.
- Panel C (Mean 22.4 mg/dL): Repeatability SD 0.13, %CV 0.6; Within-Laboratory SD 0.17, %CV 0.7; Reproducibility SD 1.12, %CV 5.0.
Accuracy:
Study Type: Bias estimation relative to Doumas Total Bilirubin reference method.
Key Results: Bias ranged from -0.1% to 3.7%.
Lower Limits of Measurement:
Study Type: Based on guidance from CLSI EP17-A2.
Key Results:
- LoB: 0.02 mg/dL
- LoD: 0.04 mg/dL
- LoQ: 0.07 mg/dL
Linearity:
Study Type: Based on guidance from CLSI EP06-A.
Key Results: Linear across the analytical measuring interval of 0.1 to 25.0 mg/dL.
Potentially Interfering Endogenous and Exogenous Substances:
Study Type: Based on guidance from CLSI EP07, 3rd ed.
Key Results: No significant interference (within ± 10%) for Hemoglobin (1000 mg/dL), Total protein (15 g/dL), Triglycerides (1500 mg/dL), 4-Hydroxypropranolol glucuronide (0.2 mg/dL), Acetaminophen (160 mg/L), Acetylcysteine (150 mg/L), Acetylsalicylic acid (30 mg/L), Ampicillin-Na (80 mg/L), Ascorbic acid (60 mg/L), Biotin (4250 ng/mL), Ca-dobesilate (60 mg/L), Cefoxitin (6600 mg/L), Cyanokit (hydroxocobalamin) (2259 mg/L), Cyclosporine (2 mg/L), Doxycycline (20 mg/L), Eltrombopag (300 mg/L), Ibuprofen (220 mg/L), Iron dextran (60 mg/L), Levodopa (8 mg/L), Methyldopa (25 mg/L), Metronidazole (130 mg/L), Oxytetracycline (12 mg/L), Phenylbutazone (330 mg/L), Propranolol (0.1 mg/dL), Rifampicin (50 mg/L), Sodium heparin (4 U/mL), Theophylline (1,3-dimethylxanthine) (60 mg/L).
Interference beyond ± 10% was observed for Indican (2 mg/dL interferent level, 2 mg/dL analyte level, 17% interference) and Indocyanine green (10 mg/L interferent level, 2 mg/dL analyte level, 9% interference).
Method Comparison:
Study Type: Based on guidance from CLSI EP09c, 3rd ed., using Passing-Bablok regression.
Sample Size: Serum (n=167), Neonatal serum (n=163).
Key Results:
- Serum: Correlation Coefficient 1.00, Intercept -0.03, Slope 1.03. Concentration Range 0.1–22.5 mg/dL.
- Neonatal serum: Correlation Coefficient 1.00, Intercept 0.00, Slope 1.00. Concentration Range 0.2–22.8 mg/dL.
Dilution Verification:
Study Type: Based on guidance from CLSI EP34 1st ed.
Key Results:
- Automated dilution: % recovery 96.3% to 104.4%; imprecision 1.6% to 2.5% (%CV).
- Manual dilution: % recovery 95.0% to 106.7%; imprecision 2.2% to 4.9% (%CV).
Both demonstrated acceptable performance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
ARCHITECT Total Bilirubin (K121985)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1110 Bilirubin (total or direct) test system.
(a)
Identification. A bilirubin (total or direct) test system is a device intended to measure the levels of bilirubin (total or direct) in plasma or serum. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal distruction of red blood cells, if used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder block.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a smaller font.
December 29, 2022
Abbott Ireland Diagnostics Division Magdalena Suszko Associate Director Regulatory Affairs Lisnarnuck, Longford Co. Longford, Ireland
Re: K223324
Trade/Device Name: Total Bilirubin2 Regulation Number: 21 CFR 862.1110 Regulation Name: Bilirubin (total or direct) test system Regulatory Class: Class II Product Code: CIG, MQM Dated: October 27, 2022 Received: October 31, 2022
Dear Magdalena Suszko:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Marianela Perez-torres -S
Marianela Perez-Torres, Ph.D. Acting Director Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K223324
Device Name Total Bilirubin2
Indications for Use (Describe)
The Total Bilirubin2 assay is used for the quantitation of total bilirubin in human serum or plasma, of adults and neonates, on the ARCHITECT c System.
Measurement of total bilirubin, an organic compound formed during the normal destruction of red blood cells, is used in the diagnosis and treatment of liver, hematological, and metabolic disorders, including hepatitis and disorders of the biliary tract. In newborn infants, the Total Bilirubin2 assay is intended to measure the levels of total bilirubin (conjugated and unconjugated) in serum or plasma to aid in the diagnosis and management of neonatal jaundice and hemolytic disease of the newborn.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary (Summary of Safety and Effectiveness)
This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Amendments (SMDA) of 1990 and 21 CFR §807.92.
I. 510(k) Number
II. Applicant Name
Abbott Ireland Diagnostics Division Lisnamuck, Longford Co. Longford Ireland
Primary contact person for all communications:
Magdalena Suszko, Associate Director, Regulatory Affairs Abbott Laboratories, Diagnostics Division Phone (224) 667-9025 Fax (224) 667-4836
Secondary contact person for all communications:
Elizabeth Molina Campos, Project Manager, Regulatory Affairs Abbott Laboratories, Diagnostics Division Phone (224) 667-0037 Fax (224) 667-4836
Date Summary Prepared: December 20, 2022
III. Device Name
Trade Name: Total Bilirubin2
Device Classification: Class II Classification Name: Bilirubin (total or direct) test system. Governing Regulation Number: 21 CFR §862.1110 Product Code: CIG
4
Device Classification: Class I, reserved Classification Name: Bilirubin (total and unbound) in the neonate test system Governing Regulation Number: 21 CFR §862.1113 Product Code: MQM
IV. Predicate Device
ARCHITECT Total Bilirubin (K121985)
V. Description of Device
A. Principles of the Procedure
Total (conjugated and unconjugated) bilirubin couples with a diazo reagent in the presence of a surfactant to form azobilirubin. The diazo reaction is accelerated by the addition of surfactant as a solubilizing agent. The increase in absorbance at 548 nm due to azobilirubin is directly proportional to the total bilirubin concentration.
Methodology: Diazonium salt
B. Reagents
The configurations of the Total Bilirubin2 reagent kits are described below.
| List Number | ||
|---|---|---|
| 04T0920 | 04T0930 | |
| Tests per cartridge set | 225 | 450 |
| Number of cartridge sets per kit | 4 | 8 |
| Tests per kit | 900 | 3600 |
| Reagent 1 (R1) | 44.5 mL | 85.9 mL |
| Reagent 2 (R2) | 14.5 mL | 26.7 mL |
Active ingredient: Brij L23 (233.333 mL/L). R1
R2 Active ingredients: 2,4-dichlorobenzenediazonium 1,5naphthalenedisulfonate hydrate (1845.000 mg/L) and Brij L23 (100.000 mL/L).
VI. Intended Use of the Device
The Total Bilirubin2 assay is used for the quantitation of total bilirubin in human serum or plasma, of adults and neonates, on the ARCHITECT c System.
5
Measurement of total bilirubin, an organic compound formed during the normal and abnormal destruction of red blood cells, is used in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders, including hepatitis and disorders of the biliary tract. In newborn infants, the Total Bilirubin2 assay is intended to measure the levels of total bilirubin (conjugated and unconjugated)in serum or plasma to aid in the diagnosis and management of neonatal jaundice and hemolytic disease of the newborn.
VII. Comparison of Technological Characteristics
The Total Bilirubin2 assay (subject device) is an automated clinical chemistry assay for the quantitation of total bilirubin in human serum or plasma, of adults and neonates, on the ARCHITECT c System.
The similarities and differences between the subject device and the predicate device are presented in the following table.
| Similarities and Differences Between | ||
|---|---|---|
| Device & Predicate Device: | ||
| Device: | ||
| Total Bilirubin2 | Predicate Device: | |
| ARCHITECT Total Bilirubin | ||
| (List No. 6L45) (K121985) | ||
| General Device Similarities | ||
| Platform | ARCHITECT c8000 System | Same |
| Similarities and Differences Between | ||
| Device & Predicate Device: | ||
| Device: | ||
| Total Bilirubin2 | Predicate Device: | |
| ARCHITECT Total Bilirubin | ||
| (List No. 6L45) (K121985) | ||
| Intended Use and | ||
| Indications for | ||
| Use | The Total Bilirubin2 assay is used for the quantitation of total bilirubin in human serum or | |
| plasma, of adults and neonates, | ||
| on the ARCHITECT c System. | ||
| Measurement of total bilirubin, an | ||
| organic compound formed during the | ||
| normal and abnormal destruction of red | ||
| blood cells, is used in the diagnosis and | ||
| treatment of liver, hemolytic, | ||
| hematological, and metabolic disorders, | ||
| including hepatitis and disorders of the | ||
| biliary tract. In newborn infants, the Total | ||
| Bilirubin2 assay is intended to measure | ||
| the levels of bilirubin in serum or plasma | ||
| to aid in the diagnosis and management | ||
| of neonatal jaundice and hemolytic | ||
| disease of the newborn. | The ARCHITECT Total Bilirubin | |
| assay is used for the quantitation of | ||
| total bilirubin in human serum or | ||
| plasma on the ARCHITECT c8000 | ||
| system. Measurement of total | ||
| bilirubin, an organic compound | ||
| formed during the normal and | ||
| abnormal destruction of red blood | ||
| cells, is used in the diagnosis and | ||
| treatment of liver, hemolytic | ||
| hematological and metabolic | ||
| disorders, including hepatitis and | ||
| gall bladder block. | ||
| A bilirubin (total and unbound) in | ||
| the neonate test system is a device | ||
| intended to measure the levels of | ||
| bilirubin (total and unbound) in the | ||
| blood (serum) of newborn infants | ||
| to aid in indicating the risk of | ||
| bilirubin encephalopathy | ||
| (kernicterus). | ||
| Methodology | Diazonium salt | Same |
| Specimen Type | Human serum or plasma | Same |
| Assay Principle / | ||
| Principle of | ||
| Procedure | Total (conjugated and unconjugated) | |
| bilirubin couples with a diazo reagent in | ||
| the presence of a surfactant to form | ||
| azobilirubin. The diazo reaction is | ||
| accelerated by the addition of surfactant | ||
| as a solubilizing agent. The increase in | ||
| absorbance at 548 nm due to azobilirubin | ||
| is directly proportional to the total | ||
| bilirubin concentration. | Same | |
| Standardization | Doumas method | Same |
| Use of Calibrators | Yes | Same |
| Use of Controls | Yes | Same |
| Similarities and Differences Between | ||
| Device & Predicate Device: | ||
| Device: | ||
| Total Bilirubin2 | Predicate Device: | |
| ARCHITECT Total Bilirubin | ||
| (List No. 6L45) (K121985) | ||
| Assay Range | Analytical Measuring Interval: | |
| 0.1–25.0 mg/dL | ||
| Extended Measuring Interval: | ||
| 25.0–125.0 mg/dL | ||
| Reportable Interval: | ||
| 0.1–125.0 mg/dL | Same | |
| Tube Types | Serum: |
- Serum tubes
- Serum separator tubes
Plasma: - Dipotassium EDTA tubes
- Lithium heparin tubes
- Lithium heparin separator tubes
- Sodium heparin tubes | Same |
| General Device Differences | | |
| Lower Limits of
Measurement | Limit of Blank: 0.02 mg/dL
Limit of Detection: 0.04 mg/dL
Limit of Quantitation: 0.07 mg/dL | Limit of Blank: 0.01 mg/dL
Limit of Detection: 0.05 mg/dL
Limit of Quantitation: 0.07 mg/dL |
6
7
8
VIII. Summary of Nonclinical Performance
All performance characteristics were obtained using the ARCHITECT c8000 System.
A. Reportable Interval
Based on the limit of detection (LoD), limit of quantitation (LoQ), precision, and linearity, the ranges over which results can be reported are provided below according to the definitions from CLSI EP34, 1st ed. *
| mg/dL | |
|---|---|
| Analytical Measuring Interval (AMI)a | 0.1-25.0 |
| Extended Measuring Interval (EMI)b | 25.0-125.0 |
| Reportable Intervalc | 0.1-125.0 |
ª AMI: The AMI is determined by the range of values in mg/dL that demonstrated acceptable performance for linearity, imprecision, and bias. NOTE: The observed LoQ has been rounded up to the number of decimal places defined in the assay file.
b EMI: The EMI extends from the upper limit of quantitation (ULoQ) to the ULoQ × sample dilution.
^ The reportable interval extends from the LoD (rounded up to the number of decimal places defined in the assay file) to the upper limit of the EMI.
NOTE: The Low Linearity value of the assay file corresponds to the lower limit of the AMI. Samples with a total bilirubin value below 0.1 mg/dL are reported as "+ Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition. CLSI Document EP05-A3. Wayne, PA: CLSI; 2014.
11
D. Lower Limits of Measurement
A study was performed based on guidance from CLSI EP17-A2.8 Testing was conducted using 3 lots of the Total Bilirubin2 reagents on each of 2 instruments over a minimum of 3 days. The maximum observed limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) values are summarized below.
| mg/dL | |
|---|---|
| LoBa | 0.02 |
| LoDb | 0.04 |
| LoQc | 0.07 |
4 The LoB represents the 95th percentile from n ≥ 60 replicates of zero-analyte samples.
b The LoD represents the lowest concentration at which the analyte can be detected with 95% probability based on n ≥ 60 replicates of low-analyte level samples.
& The LoQ is defined as the lowest concentration at which a maximum allowable precision of 20% CV was met and was determined from n ≥ 60 replicates of low-analyte level samples.
E. Linearity
A study was performed based on guidance from CLSI EP06-A.** This assay is linear across the analytical measuring interval of 0.1 to 25.0 mg/dL.
§ Clinical and Laboratory Standards Institute (CLSI). Evaluation of Detection Capability for Clinical Laboratory Measurent Procedures; Approved Guideline-Second Edition. CLSI Document EP17-A2. Wayne, PA: CLSI; 2012.
** Clinical and Laboratory Standards Institute (CLSI). Evaluetitative Measurement Procedures: A Staristical Approach; Approved Guideline. CLSI Document EP06-A. Wayne, PA: CLSI; 2003.
12
F. Potentially Interfering Endogenous and Exogenous Substances
Potentially Interfering Endogenous Substances
A study was performed based on guidance from CLSI EP07, 3rd ed. Each substance was tested at 2 levels of the analyte (approximately 2 mg/dL and 15 mg/dL). No significant interference (interference within ± 10%) was observed at the following concentrations.
| No Significant Interference (Interference within ± 10%) | |
|---|---|
| Potentially Interfering Substance | Interferent Level |
| Hemoglobin | 1000 mg/dL |
| Indican | 1 mg/dL |
| Total protein | 15 g/dL |
| Triglycerides | 1500 mg/dL |
Interference beyond ± 10% (based on 95% Confidence Intervals [CI]) was
observed at the concentration shown below for the following substance.
| Interference beyond ± 10% (based on 95% Confidence Interval [CI]) | ||||
|---|---|---|---|---|
| Potentially Interfering | ||||
| Substance | Interferent Level | Analyte Level | % Interference | |
| (95% CI) | ||||
| Indican | 2 mg/dL | 2 mg/dL | 17% | |
| (15%, 19%) |
Potentially Interfering Exogenous Substances
A study was performed based on guidance from CLSI EP07, 3rd ed. Each substance was tested at 2 levels of the analyte (approximately 2 mg/dL and 15 mg/dL).
Clinical and Laboratory Standards Institute (CLS). Interference Testing in Clinical Chemistry. 3rd ed. CLSI Guideline EP07. Wayne, PA: CLSI; 2018.
Clinical and Laboratory Standards Institute (CLS). Interference Testing in Clinical Chemistry. 3rd ed. CLSI Guideline EP07. Wayne, PA: CLSI; 2018.
13
No significant interference (interference within ± 10%) was observed at the following concentrations.
| No Significant Interference (Interference within ± 10%) | |
|---|---|
| Potentially Interfering Substance | Interferent Level |
| 4-Hydroxypropranolol glucuronide | 0.2 mg/dL |
| Acetaminophen | 160 mg/L |
| Acetylcysteine | 150 mg/L |
| Acetylsalicylic acid | 30 mg/L |
| Ampicillin-Na | 80 mg/L |
| Ascorbic acid | 60 mg/L |
| Biotin | 4250 ng/mL |
| Ca-dobesilate | 60 mg/L |
| Cefoxitin | 6600 mg/L |
| Cyanokit (hydroxocobalamin) | 2259 mg/L |
| Cyclosporine | 2 mg/L |
| Doxycycline | 20 mg/L |
| Eltrombopag | 300 mg/L |
| Ibuprofen | 220 mg/L |
| Indocyanine green | 5 mg/L |
| Iron dextran | 60 mg/L |
| Levodopa | 8 mg/L |
| Methyldopa | 25 mg/L |
| Metronidazole | 130 mg/L |
| Oxytetracycline | 12 mg/L |
| Phenylbutazone | 330 mg/L |
| Propranolol | 0.1 mg/dL |
| No Significant Interference (Interference within ± 10%) | |
| Potentially Interfering Substance | Interferent Level |
| Rifampicin | 50 mg/L |
| Sodium heparin | 4 U/mL |
| Theophylline (1,3-dimethylxanthine) | 60 mg/L |
14
Interference beyond ± 10% (based on 95% Confidence Intervals [CI]) was
observed at the concentrations shown below for the following substance.
| Interference beyond ± 10% (based on 95% Confidence Interval [CI]) | |||||||
|---|---|---|---|---|---|---|---|
| Potentially Interfering | |||||||
| Substance | Interferent Level | Analyte Level | % Interference | ||||
| (95% CI) | |||||||
| Indocyanine green | 10 mg/L | 2 mg/dL | 9% | ||||
| (8%, 11%) |
G. Method Comparison
A study was performed based on guidance from CLSI EP09c, 3rd ed.t* using the Passing-Bablok regression method.
| Total Bilirubin2 vs Total Bilirubin on the ARCHITECT c System | ||||||
|---|---|---|---|---|---|---|
| n | Units | Correlation Coefficient | Intercept | Slope | Concentration Range | |
| Serum | 167 | mg/dL | 1.00 | -0.03 | 1.03 | 0.1–22.5 |
| Neonatal serum | 163 | mg/dL | 1.00 | 0.00 | 1.00 | 0.2–22.8 |
** Clinical and Laboratory Standards Institute (CLSI). Measurement Procedure Comparison Using Patient Samples. 3rd ed. CLSI Guideline EP09c. Wayne, PA: CLSI; 2018.
15
H. Tube Type
A study was performed to evaluate the suitability of specific blood collection tube types for use with the Total Bilirubin2 assay. Samples were collected from a minimum of 40 donors and evaluated across tube types. The following blood collection tube types were determined to be acceptable for use with the Total Bilirubin2 assay:
Serum
- . Serum tubes
- . Serum separator tubes
Plasma
- . Dipotassium EDTA tubes
- . Lithium heparin tubes
- . Lithium heparin separator tubes
- . Sodium heparin tubes
I. Dilution Verification
A study was performed based on guidance from CLSI EP34 1st ed. * to evaluate the performance of the automated dilution protocol and manual dilution procedure of the Total Bilirubin2 assay (LN 04T09) on the ARCHITECT c8000 instrument.
Five samples were prepared to have total bilirubin concentrations within the extended measuring interval (EMI) of the Total Bilirubin2 assay by spiking total bilirubin stock into a serum pool to the target concentration values of 30.0 mg/dL, 55.0 mg/dL, 70.0 mg/dL, 90.0 mg/dL, and 110.0 mg/dL.
The performance of the automated dilution protocol (1:5) and manual dilution procedure (1:5) was considered acceptable if, for samples within the EMI, the dilution recovery was within or equal to 100% ± 10% when comparing auto-diluted or manually
Clinical and Laboratory Standards Institute (CLS). Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking. 1st ed. CLSI Guideline EP34. Wayne, PA: CLSI; 2018.
16
diluted samples to target or assigned concentrations and the imprecision was ≤ 7 %CV for the automated dilution protocol and ≤ 8 %CV for manual dilution procedure.
The % recovery results of 96.3% to 104.4% for the automated dilution, and 95.0% to 106.7% for the manual dilution, demonstrated acceptable performance.
The imprecision results of 1.6% to 2.5% for the automated dilution, and 2.2% to 4.9% for the manual dilution, demonstrated imprecision ≤ 7 %CV for the automated dilution protocol and ≤ 8 %CV for manual dilution procedure.
IX. Summary of Clinical Performance
This section does not apply.
X. Conclusion Drawn from Nonclinical Laboratory Studies
The results presented in this 510(k) premarket notification demonstrate that the performance of the subject device, Total Bilirubin2 (List No. 04T09), is substantially equivalent to the predicate device, Total Bilirubin (List No. 6L45, K121985).
The similarities and differences between the subject device and predicate device are presented in Section 5-VII.
There is no known potential adverse effect to the operator when using this in vitro device according to the Total Bilirubin2 reagent package insert instructions.